GW hails tests on pain drug

My Account
Logout

Create an Evening Standard Account

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Welcome! Sign in here

Use your social network

Save time by using your existing account to sign in to Evening Standard

We'll never share your information or post anything to your account without your permission

Forgot your password ?

Registration

* indicates fields that are mandatory

Email *

Password *

Confirm Password *

First name *

Surname *

Postcode *

Country *

Mobile phone number

Username *

Gender *

Year of birth *

When you sign up...

You will have access to all our online competitions, discounted offers and can post comments on our site.

You will also receive The Weekender newsletter sent every Thursday - it’s full of fantastic offers and ideas for the weekend. You can update your email preferences in your account page when you log in.

Other newsletters and emails

Homes & Property Newsletter - Yes I want to receive the weekly email with all the latest news on property in the capital

Occasionally we would also like to send you relevant emails detailing specific offers either from ourselves or carefully selected partners. If you would prefer not to receive these then please tick the appropriate boxes below. We will never pass on your details.

I do not want to receive additional offers and information from the Evening Standard

I do not want to receive additional offers and information sent by Evening Standard on behalf of carefully selected partners

Terms and Conditions

* I have read, understood and agree to be bound by the terms and conditions of Evening Standard

Registration

Mail Sent for Registration Confirmation.

A confirmation email has been sent. Please activate your account by clicking on the activation link sent in your mail box.

The company has spent years attempting to convince regulators of the efficacy of its Sativex medicine.

Today it said the latest tests had been described by regulators as being sufficient to satisfy the need for long term efficacy data.

In it, some of a group of 42 patients suffering from multiple sclerosis who had previously been taking Sativex had their doses of the drug replaced by a placebo. Those who were taken off the Sativex reported increased pain and difficulty sleeping.

Those kept on Sativex maintained or improved their levels of pain and sleeplessness. Dr Stephen Wright, research and development director at GW, said: "It is encouraging to note that if the difference between Sativex and placebo achieved in the results today are replicated in the Phase III MS study, it will meet his objectives."